Keene C - Search Results

1

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.

Zhao Y, Griesel R, Omar Z, Simmons B, Hill A, van Zyl G, Keene C, Maartens G, Meintjes G. Zhao Y, et al. Among authors: keene c. Clin Infect Dis. 2023 May 24;76(10):1832-1840. doi: 10.1093/cid/ciad023. Clin Infect Dis. 2023. PMID: 36645792 Free PMC article. Clinical Trial.

2

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.

Keene CM, Griesel R, Zhao Y, Gcwabe Z, Sayed K, Hill A, Cassidy T, Ngwenya O, Jackson A, van Zyl G, Schutz C, Goliath R, Flowers T, Goemaere E, Wiesner L, Simmons B, Maartens G, Meintjes G. Keene CM, et al. AIDS. 2021 Jul 15;35(9):1423-1432. doi: 10.1097/QAD.0000000000002936. AIDS. 2021. PMID: 33973876 Free PMC article.

3

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial.

Zhao Y, Keene C, Griesel R, Sayed K, Gcwabe Z, Jackson A, Ngwenya O, Schutz C, Goliath R, Cassidy T, Goemaere E, Hill A, Maartens G, Meintjes G. Zhao Y, et al. Among authors: keene c. Wellcome Open Res. 2021 Feb 17;6:33. doi: 10.12688/wellcomeopenres.16597.1. eCollection 2021. Wellcome Open Res. 2021. PMID: 36017341 Free PMC article.

4

Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.

Keene CM, Cassidy T, Zhao Y, Griesel R, Jackson A, Sayed K, Omar Z, Hill A, Ngwenya O, Van Zyl G, Flowers T, Goemaere E, Maartens G, Meintjes G. Keene CM, et al. J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):422-429. doi: 10.1097/QAI.0000000000003157. J Acquir Immune Defic Syndr. 2023. PMID: 36706364 Free PMC article.

5

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.

Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene CM, Hill AM, Meintjes G, Maartens G. Griesel R, et al. Lancet HIV. 2023 Jul;10(7):e433-e441. doi: 10.1016/S2352-3018(23)00081-4. Epub 2023 May 22. Lancet HIV. 2023. PMID: 37230101 Free PMC article. Clinical Trial.

6

Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.

van Heerden JK, Meintjes G, Barr D, Zhao Y, Griesel R, Keene CM, Wiesner L, Galileya LT, Denti P, Maartens G. van Heerden JK, et al. J Acquir Immune Defic Syndr. 2024 Mar 1;95(3):260-267. doi: 10.1097/QAI.0000000000003341. J Acquir Immune Defic Syndr. 2024. PMID: 38408216 Free PMC article.

7

A Competing-Risk Approach for Modeling Length of Stay in Severe Malaria Patients in South-East Asia and the Implications for Planning of Hospital Services.

Keene CM, Dondorp A, Crawley J, Ohuma EO, Mukaka M. Keene CM, et al. Clin Infect Dis. 2018 Sep 14;67(7):1053-1062. doi: 10.1093/cid/ciy211. Clin Infect Dis. 2018. PMID: 29562258 Free PMC article. Clinical Trial.

8

A cluster randomized controlled trial of extending ART refill intervals to six-monthly for anti-retroviral adherence clubs.

Wilkinson L, Grimsrud A, Cassidy T, Orrell C, Voget J, Hayes H, Keene C, Steele SJ, Gerstenhaber R. Wilkinson L, et al. Among authors: keene c. BMC Infect Dis. 2019 Jul 30;19(1):674. doi: 10.1186/s12879-019-4287-6. BMC Infect Dis. 2019. PMID: 31362715 Free PMC article.

9

Twenty-four-month outcomes from a cluster-randomized controlled trial of extending antiretroviral therapy refills in ART adherence clubs.

Cassidy T, Grimsrud A, Keene C, Lebelo K, Hayes H, Orrell C, Zokufa N, Mutseyekwa T, Voget J, Gerstenhaber R, Wilkinson L. Cassidy T, et al. Among authors: keene c. J Int AIDS Soc. 2020 Dec;23(12):e25649. doi: 10.1002/jia2.25649. J Int AIDS Soc. 2020. PMID: 33340284 Free PMC article. Clinical Trial.

10

Supporting re-engagement with HIV services after treatment interruption in South Africa: a mixed method program evaluation of MSF's Welcome Service.

Arendse KD, Walker C, Pfaff C, Lebelo K, Cassidy T, Isaakidis P, von der Heyden E, Abdullah F, Ellman T, Katz IT, Euvrard J, Keene CM. Arendse KD, et al. Among authors: keene cm. Sci Rep. 2024 Mar 27;14(1):7317. doi: 10.1038/s41598-024-57774-9. Sci Rep. 2024. PMID: 38538754 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

424 results

Search Page